NCT03883113View on ClinicalTrials.gov

Efficacy of MVA-NP+M1 in the Influenza H3N2 Human Challenge Model

PHASE2CompletedINTERVENTIONAL
Enrollment

145

Participants

Timeline

Start Date

June 3, 2019

Primary Completion Date

December 16, 2019

Study Completion Date

April 17, 2020

Conditions
Influenza
Interventions
BIOLOGICAL

MVA-NP+M1

Trial Vaccine

BIOLOGICAL

Saline

Sodium Chloride Placebo

BIOLOGICAL

H3N2 (A/Belgium/2417/2015)

Challenge Agent

Trial Locations (1)

2060

SGS Life Sciences, Clinical Pharmacology Unit (CPU), Antwerp

Sponsors
All Listed Sponsors
lead

Barinthus Biotherapeutics

INDUSTRY